A detailed history of Sheaff Brock Investment Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sheaff Brock Investment Advisors, LLC holds 7,118 shares of HALO stock, worth $324,936. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,118
Previous 6,611 7.67%
Holding current value
$324,936
Previous $346,000 17.63%
% of portfolio
0.04%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$51.3 - $64.42 $26,009 - $32,660
507 Added 7.67%
7,118 $407,000
Q2 2024

Jul 30, 2024

BUY
$37.81 - $52.4 $40,494 - $56,120
1,071 Added 19.33%
6,611 $346,000
Q1 2024

May 14, 2024

BUY
$33.68 - $41.95 $186,587 - $232,403
5,540 New
5,540 $225,000
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $185,077 - $274,612
4,620 New
4,620 $262,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.36B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Sheaff Brock Investment Advisors, LLC Portfolio

Follow Sheaff Brock Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheaff Brock Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sheaff Brock Investment Advisors, LLC with notifications on news.